FAPI PET/MR imaging of fibroblast activity in glioblastoma
Official title: Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.
Run by Jules Bordet Institute · NCT07119294 · Data updated 2026-11-12
This will try a FAPI PET/MR scan to image fibroblast activation in adults with a suspected or recurrent glioblastoma.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Jules Bordet Institute Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | August 2025 |
| Main results expected | December 2027 |
| Study ends | June 2028 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT07119294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a brain lesion suspected to be glioblastoma or with suspected recurrence, ECOG performance status ≤3, who can undergo PET/MR and provide informed consent are ideal candidates.
✕Probably not a fit
Pregnant or breastfeeding patients, those with uncontrolled major medical or neuropsychiatric conditions, claustrophobia preventing MR, or known hypersensitivity to the tracer or gadolinium are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional imaging protocol uses a radiotracer that binds fibroblast activation protein (FAP) combined with PET/MR to visualize cancer-associated fibroblasts in and around brain tumors. Eligible adults with a brain lesion suspected to be glioblastoma or with suspected recurrence will undergo the FAPI PET/MR scan, including standard MR sequences and tracer administration. Images will be analyzed to map FAP expression and compare tracer uptake with conventional imaging features and clinical information. The procedure excludes pregnant or lactating patients and those with known hypersensitivity to the tracer or gadolinium contrast.
Why it matters
Potential benefit: If successful, the technique could improve tumor visualization and help distinguish active tumor from treatment-related changes, potentially guiding surgical or treatment decisions.
How similar studies have gone: FAPI PET has shown promising imaging results in several non-brain cancers and FAP expression has been reported in glioblastoma, but imaging cancer-associated fibroblasts in brain tumors is a relatively new approach with limited validation to date.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above or equal to 18 years * Patients with a brain lesion suspected of glioblastoma based on neuroimaging data or patients with suspected recurrence of glioblastoma * ECOG performance status ≤ 3 * Signed Informed Consent form (ICF) obtained prior to any study related procedure. Exclusion Criteria: * Pregnant and/or lactating women. * Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study. * Claustrophobic patient * Known hypersensitivity reactions to the FAPI or to any excipients, or to gadolinium-based contrast agents (GBCAs).
Where it's running
-
Institut Jules Bordet
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Amélie Castiaux, MD
- Email: amelie.castiaux@hubruxelles.be
- Phone: 02.555.81.93
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Lixumistat window of opportunity in newly diagnosed glioblastoma
This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.
-
Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care
A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.
-
Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care
This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.